Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
The bill creates an exception to the Medicare drug price negotiation program for certain "research and development-intensive" small biotech manufacturers beginning with the initial price applicability year 2029. A "small biotech manufacturer" is defined as having five or fewer qualifying single-source drugs and not being owned or controlled by a covered foreign government.
Progressives emphasize higher Medicare costs and access harms.
Relative to its intended legislative type, this bill is a clearly targeted substantive amendment that establishes eligibility criteria and an administrative application/appeal pathway to exclude certain qualifying drugs from the Medicare negotiation program.
The bill creates an exception to the Medicare drug price negotiation program for certain "research and development-intensive" small biotech manufacturers beginning with the initial price applicability year 2029.
A "small biotech manufacturer" is defined as having five or fewer qualifying single-source drugs and not being owned or controlled by a covered foreign government.
To qualify for the exception the manufacturer must invest a defined percentage of net revenue (30–70%, depending on the number of qualifying drugs) averaged over the prior three years in R&D, submit annual applications with revenue and R&D data, and may appeal adverse determinations.
As a stand-alone statutory carve-out reducing Medicare savings, it faces substantial policy opposition; more viable only as part of a larger negotiated package.
Relative to its intended legislative type, this bill is a clearly targeted substantive amendment that establishes eligibility criteria and an administrative application/appeal pathway to exclude certain qualifying drugs from the Medicare negotiation program. It integrates with existing statutory cross-references and specifies key definitions and thresholds.
Progressives emphasize higher Medicare costs and access harms.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize higher Medicare costs and access harms.
Likely skeptical because the exception narrows Medicare’s price negotiation authority for prescription drugs, potentially increasing costs for patients and taxpayers.
May acknowledge support for small biotech R&D but will worry the thresholds could be gamed and that lost negotiation leverage will reduce affordability and access.
Sees a plausible tradeoff between protecting nascent biotech innovation and preserving Medicare cost controls.
Will want strong verification, narrow eligibility, and fiscal offsets to prevent budgetary leakage while recognizing the need to support small firms.
Favorable because it limits federal price-setting reach and protects small, innovation-focused biotech firms from policies that could undermine growth.
Values the emphasis on R&D investment and restrictions on foreign-government-controlled entities.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
As a stand-alone statutory carve-out reducing Medicare savings, it faces substantial policy opposition; more viable only as part of a larger negotiated package.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize higher Medicare costs and access harms.
As a stand-alone statutory carve-out reducing Medicare savings, it faces substantial policy opposition; more viable only as part of a large…
Relative to its intended legislative type, this bill is a clearly targeted substantive amendment that establishes eligibility criteria and an administrative application/appeal pathway to exclude certain qualifying drugs…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.